Inclusion Criteria : 
  -  Frailᵃ male patients with prostate cancer who will start treatment with enzalutamide within label
  -  Age at least 18 years
  -  Patient who are able and willing to give written informed consent prior to screening
  -  Patients from whom it is possible to collect blood samples
  -  Patients who are willing to answer the questionnaires and test
  -  Life expectancy of > 6 months
  -  Capable of understanding and answering Dutch tests and questionnaires , as determined by the investigator
ᵃ Frail is defined as : 
  -  a score on the comprehensive G8 assessment with cut - off ≤ 14 points and
  -  score ≥ grade 1 for Central Nervous Disorders according to the Common Toxicity Criteria Adverse Event ( CTCAE ) criteria , of one of the following : Fatigue , Concentration impairment , cognitive disturbance , amnesia , depressed level of consciousness , memory impairment , hypersomnia. 
Exclusion Criteria : 
  -  change in dose of opioids / sedatives / benzodiazepines during last 2 weeks before study ) 
  -  Use of psychostimulants such as methylphenidate within 1 week of start of study
  -  Diagnosed with medical conditions that affect cognition : Dementia , Alzheimer disease , Parkinson's disease , psychiatric disorders that affect cognition other than depression or anxiety complaints related to the disease
  -  Active infection or other comorbidities that may contribute to REDOSE , February 2019 Page 7 of 53 fatigue or cognition change within 4 weeks of study entry
  -  Clinical relevant anaemia
  -  MoCa score < 20 
  -  Hypersensitivity to the active substance or to any of the excipients.